Tiziana Life Sciences, Ltd. - שינוי בהכנסות משנה לשנה ב-12 החודשים האחרונים TLSA

Tiziana Life Sciences (TLSA) relies on the commercialization of nasal antibodies to combat Alzheimer's disease. This TTM annual revenue growth chart available in the GURU.Markets system shows 0.00 as the latest metric reading. Prospects depend on test results and funding, while the proprietary drug delivery platform could provide the company with pricing power.
tizianalifesciences.com (TLSA) - פילוחי מדדים ודוחות פיננסיים

For Tiziana Life Sciences (TLSA), which is currently in the clinical deployment stage of therapy for autoimmune pathologies, it is critical to align broad market capture ambitions with actual scaling. By analyzing the year-over-year (YoY) dynamics of commercial revenues over a rolling year, an investor assesses the revenue growth rate over the last 12 months relative to the same period last year, which allows for an objective confirmation of the company's real operational expansion.